JOIN US
Liquid Biopsy in Advanced NSCLC: Stay Up to Date
When a liquid biopsy report identifies a targetable driver, treatment decisions are clear. When there is no driver identified, the next steps are more uncertain. Expert speakers will present their perspectives on liquid biopsy for treatment selection in NSCLC and discuss emerging biomarker ctDNA tumor fraction reported on Foundation Medicine’s liquid biopsy test.
JULY 23, 2024
12:30 pm
HATIM HUSAIN, MD
Internationally Recognized Expert
in Lung Cancer
HOLLI DILKS, PhD
Sr. Director, Global Field Medical
Foundation Medicine
JENNIFER MILLS, PhD
Moderator
Vice President, Medical Affairs,
Foundation Medicine